Teva said that the court has issued an order temporarily enjoining the company from further sales of generic Famciclovir tablets, AB-rated to Novartis’s Famvir tablets. The injunction will remain in place pending consideration of Novartis’s emergency motion for a stay pending appeal.
Israel-based Teva said that its response to Novartis’s emergency motion is due on September 11, 2007.